BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 12873887)

  • 1. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
    Ferenczi K; Yawalkar N; Jones D; Kupper TS
    Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis.
    Haley HR; Davis DA; Sams WM
    J Am Acad Dermatol; 1999 Nov; 41(5 Pt 2):880-3. PubMed ID: 10534677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of T-cell receptor gene rearrangement for predicting clinical outcome in patients with cutaneous T-cell lymphoma: a comparison of Southern blot and polymerase chain reaction methods.
    Juarez T; Isenhath SN; Polissar NL; Sabath DE; Wood B; Hanke D; Haycox CL; Wood GS; Olerud JE
    Arch Dermatol; 2005 Sep; 141(9):1107-13. PubMed ID: 16172307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches in cutaneous lymphoma.
    Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
    Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
    Rook AH; Gottlieb SL; Wolfe JT; Vowels BR; Sood SS; Niu Z; Lessin SR; Fox FE
    Clin Exp Immunol; 1997 Jan; 107 Suppl 1():16-20. PubMed ID: 9020930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased T-cell receptor excision circles in cutaneous T-cell lymphoma.
    Yamanaka K; Yawalkar N; Jones DA; Hurwitz D; Ferenczi K; Eapen S; Kupper TS
    Clin Cancer Res; 2005 Aug; 11(16):5748-55. PubMed ID: 16115912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma.
    Heald P; Yan SL; Edelson R
    Arch Dermatol; 1994 Feb; 130(2):198-203. PubMed ID: 8304758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal photopheresis reduces the number of mononuclear cells that produce pro-inflammatory cytokines, when tested ex-vivo.
    Bladon J; Taylor P
    J Clin Apher; 2002; 17(4):177-82. PubMed ID: 12494410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis.
    Lee CH; Mamelak AJ; Vonderheid EC
    Int J Dermatol; 2007 Nov; 46(11):1198-204. PubMed ID: 17988344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of phototherapy in cutaneous T-cell lymphoma.
    Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
    J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
    Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
    Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of cutaneous T-cell lymphomas].
    Rappersberger K; Ortel B; Forstinger C; Wolff K
    Wien Klin Wochenschr; 1994; 106(10):300-8. PubMed ID: 8053197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cutaneous T-cell lymphoma.
    Zackheim HS
    Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8+ epidermotropic cytotoxic T-cell lymphoma with peripheral blood and central nervous system involvement.
    Introcaso CE; Kim EJ; Gardner J; Junkins-Hopkins JM; Vittorio CC; Rook AH
    Arch Dermatol; 2008 Aug; 144(8):1027-9. PubMed ID: 18711076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging and management of cutaneous T-cell lymphoma.
    Scarisbrick JJ
    Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience.
    Siakantaris MP; Tsirigotis P; Stavroyianni N; Argyropoulos KV; Girkas K; Pappa V; Chondropoulos S; Papadavid E; Sakellari I; Anagnostopoulos A; Antoniou C; Dervenoulas J
    Transfus Apher Sci; 2012 Apr; 46(2):189-93. PubMed ID: 22178592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cutaneous T-cell lymphoma: an update.
    Young JW
    J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.